New Vernon Capital Holdings II’s Maravai LifeSciences MRVI Stock Holding History

New Vernon Capital Holdings II’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,160	Closed	-$164K	–	71
2023 Q2	$164K	Hold	13,160	–	–	0.11%	64
2023 Q1	$184K	Buy	13,160 +127	+1%	+$1.82K	0.14%	62
2022 Q4	$187K	Buy	+13,033	New	+$205K	0.15%	58

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

New Vernon Capital Holdings II's MRVI Position: Q3 2023 in Review

New Vernon Capital Holdings II sold out of Maravai LifeSciences (MRVI) in Q3 2023, closing a stake of 13,160 shares — an estimated $164K sold.

New Vernon Capital Holdings II first reported a position in MRVI in Q4 2022 and held it in 3 quarters. The position peaked at $187K in Q4 2022. 204 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

New Vernon Capital Holdings II reported no remaining Maravai LifeSciences position as of Q3 2023 after selling out during the quarter.
New Vernon Capital Holdings II sold 13,160 Maravai LifeSciences shares in Q3 2023, an estimated $164K.
New Vernon Capital Holdings II first reported a position in Maravai LifeSciences in Q4 2022 and held it in 3 quarters.
New Vernon Capital Holdings II's Maravai LifeSciences position peaked at $187K in Q4 2022.
204 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on New Vernon Capital Holdings II's 13F filing for Q3 2023, filed 14 Nov 2023.